ERBB2 and non-small cell lung carcinoma: An increasing number of HER2-activating missense mutations are being identified and described by multiplex next-generation sequencing (NGS) in NSCLC; however, current evidence regarding HER2-activating missense mutations in NSCLC consists mainly of case reports or studies with small sample sizes focusing on specific mutations due to their rare frequency.